KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Work In Process (2016 - 2025)

Historic Work In Process for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q3 2025 value amounting to $33.4 million.

  • Supernus Pharmaceuticals' Work In Process rose 1887.77% to $33.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.4 million, marking a year-over-year increase of 1887.77%. This contributed to the annual value of $26.7 million for FY2024, which is 1437.59% down from last year.
  • Supernus Pharmaceuticals' Work In Process amounted to $33.4 million in Q3 2025, which was up 1887.77% from $15.6 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Work In Process' 5-year high stood at $46.2 million during Q1 2022, with a 5-year trough of $9.3 million in Q1 2021.
  • For the 5-year period, Supernus Pharmaceuticals' Work In Process averaged around $28.1 million, with its median value being $27.0 million (2023).
  • Its Work In Process has fluctuated over the past 5 years, first surged by 40874.79% in 2021, then plummeted by 3599.57% in 2023.
  • Supernus Pharmaceuticals' Work In Process (Quarter) stood at $45.7 million in 2021, then plummeted by 30.63% to $31.7 million in 2022, then dropped by 1.57% to $31.2 million in 2023, then decreased by 14.38% to $26.7 million in 2024, then grew by 25.0% to $33.4 million in 2025.
  • Its last three reported values are $33.4 million in Q3 2025, $15.6 million for Q2 2025, and $18.7 million during Q1 2025.